Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Sep 3, 2024 · Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Atara Biotherapeutics Provides Update on Clinical Programs …
3 days ago · THOUSAND OAKS, Calif., January 21, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the...
Atara Biotherapeutics Provides Update on Clinical Programs …
3 days ago · About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to ...
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell …
3 days ago · Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15 million in funding through an equity line of credit. Price Action: ATRA stock is down 4.09% at $6.302 at ...
Atara Biotherapeutics (ATRA)
Nov 12, 2024 · Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory.
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16, 2025 · The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a rare cancer that develops after organ or stem cell transplants,...
Pipeline - Atara Biotherapeutics
Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases.
About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Atara Biotherapeutics Provides Regulatory and Business Update …
Jan 16, 2025 · THOUSAND OAKS, Calif., January 16, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
- Some results have been removed